CD36+/CD61+ Microparticles Correlate with the Risk of Percutaneous Cardiac Interventions in Coronary Artery Disease Patients and the Effects of Ticagrelor.
Xue ZhouXing LiuHongmei LiuShuang DouKangyin ChenXiaowei ZhangWeiding WangXuewen WangJing-Jin ChePublished in: Cardiovascular drugs and therapy (2021)
The high levels of CD36+ MPs derived from activated platelets are related to an increased risk of PCI in CAD patients. Ticagrelor significantly reduced the number of CD61+/AV+ MPs and CD36+/CD61+/AV+ MPs. This trial registration number is ChiCTR1800014908 and the date of registration is 2018.05.01.
Keyphrases
- coronary artery disease
- end stage renal disease
- percutaneous coronary intervention
- chronic kidney disease
- acute coronary syndrome
- ejection fraction
- newly diagnosed
- antiplatelet therapy
- cardiovascular disease
- coronary artery bypass grafting
- study protocol
- atrial fibrillation
- minimally invasive
- ultrasound guided
- phase iii
- nk cells